Trulieve reports USD 271 million Q2 revenue as Trulieve Cannabis stock costs EUR 8.83

Published on 10/15/2026 at 12:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted EBITDA was USD 98 million, a 36 percent margin, in the second quarter of 2026. Trulieve Cannabis stock costs EUR 8.83 on October 15, 2026 at a USD 1.70 billion market value.

Quarterly revenue and future dates

Second-quarter revenue reached USD 271 million on October 13, 2026.
Adjusted EBITDA was USD 98 million, equal to a 36 percent margin in the second quarter of 2026.
Trulieve Cannabis stock trades at EUR 8.83 at 12:30 p.m. CEST at Lang & Schwarz on October 15, 2026.
Third-quarter results are scheduled for November 5, 2026.

TRUL, US89790E1064, Illustration mit AI erstellt.

Trulieve Cannabis (ISIN US89790E1064) was trading at EUR 8.83 at Lang & Schwarz on October 15, 2026 at 12:30 p.m. CEST, while its market value stood at USD 1.70 billion. The company reported second-quarter revenue of USD 271 million on October 13, 2026, giving investors a fresh look at its first full period after the Harvest deconsolidation.

According to Benzinga, adjusted EBITDA reached USD 98 million, or a 36 percent margin, in the second quarter of 2026. Medical-only revenue was USD 222 million, up 4 percent sequentially, while operating cash flow reached USD 53 million.

Margins carry the quarterly story

The earnings mix matters because the reported net loss was USD 406 million in the second quarter of 2026, including a USD 407 million impact from the Harvest deconsolidation and equity investment. Excluding nonrecurring items, management reported net income of USD 20 million, or USD 0.11 adjusted earnings per share, according to Benzinga.

For the third quarter of 2026, management expects medical-only revenue comparable to the USD 222 million medical-only figure from the second quarter. Full-year 2026 operating cash flow is expected to reach at least USD 225 million, while capital expenditures are projected at USD 95 million, according to the same earnings-call transcript.

Three dates define the recent path

On June 10, 2026, Trulieve began trading on the New York Stock Exchange under ticker TRLV, according to Benzinga. On October 7, 2026, the company repaid approximately USD 65 million of mortgage notes, reducing outstanding debt to approximately USD 225 million, as reported by Yahoo Finance. On October 13, 2026, Trulieve reported USD 271 million in second-quarter revenue.

What does the outlook mean?

The near-term test is whether Georgia and Pennsylvania can offset seasonal pressure in Florida. The company said Georgia patient enrollment had surpassed 45,000 in the second quarter of 2026, while its Texas expansion remained subject to regulatory approvals.

Upcoming results set the next marker

Trulieve is scheduled to release third-quarter 2026 results and hold its related conference call on November 5, 2026, according to Yahoo Finance. The date will provide the first clean quarterly comparison for the medical-only structure.

Stock price remains the market marker

Trulieve Cannabis stock was trading at EUR 8.83 at Lang & Schwarz on October 15, 2026 at 12:30 p.m. CEST. The company is listed on the New York Stock Exchange under ticker TRLV and operates a vertically integrated medical cannabis business in the United States.